Eupraxia Pharmaceuticals (EPRX) Stock Price, News & Analysis

Company Overview

Eupraxia Pharmaceuticals, Inc. (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline. The company has established preclinical programs targeting additional autoimmune indications and is preparing to initiate subsequent trials as it builds clinical proof-of-concept for its Treg-focused approach.

Eupraxia’s management team comprises seasoned professionals with expertise in immunology, drug development and regulatory affairs. The leadership is committed to leveraging decades of collective experience in biopharma to guide the company’s progression from early-stage research toward potential regulatory milestones and commercial readiness. As a publicly traded company on NASDAQ, Eupraxia Pharmaceuticals aims to deliver innovative, first-in-class treatments that address unmet medical needs in chronic immune-mediated conditions.

Key Stats

• Today's Range: $5.30 to $5.41
• 50-Day Range: $5.05 to $5.84
• 52-Week Range: $2.20 to $6.20
• Volume: 30,300 shs
• Average Volume: 11,447 shs
• Market Capitalization: $193.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Buy

Eupraxia Pharmaceuticals Stock Analysis - MarketRank™

Eupraxia Pharmaceuticals scored higher than 55% of companies evaluated by MarketBeat, and ranked 510th out of 928 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Buy

Consensus Rating

Eupraxia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Eupraxia Pharmaceuticals has a consensus price target of $11.00, representing about 104.1% upside from its current price of $5.39.

Amount of Analyst Coverage

Eupraxia Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Eupraxia Pharmaceuticals are expected to grow in the coming year, from ($0.67) to ($0.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Eupraxia Pharmaceuticals is -6.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eupraxia Pharmaceuticals is -6.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.61% of the float of Eupraxia Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Eupraxia Pharmaceuticals has a short interest ratio ("days to cover") of 14.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Eupraxia Pharmaceuticals has recently decreased by 2.18%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eupraxia Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Eupraxia Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.61% of the float of Eupraxia Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Eupraxia Pharmaceuticals has a short interest ratio ("days to cover") of 14.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Eupraxia Pharmaceuticals has recently decreased by 2.18%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: N/A

News Sentiment

Eupraxia Pharmaceuticals has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Eupraxia Pharmaceuticals this week, compared to 1 article on an average week.

MarketBeat Follows

2 people have added Eupraxia Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eupraxia Pharmaceuticals insiders have not sold or bought any company stock.

EPRX Stock Analysis - Frequently Asked Questions

How have EPRX shares performed this year?

Eupraxia Pharmaceuticals' stock was trading at $3.17 at the beginning of the year. Since then, EPRX shares have increased by 70.0% and is now trading at $5.39.

How were Eupraxia Pharmaceuticals' earnings last quarter?

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) posted its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.05.

Who are Eupraxia Pharmaceuticals' major shareholders?

Top institutional investors of Eupraxia Pharmaceuticals include Scotia Capital Inc. (3.59%), Bank of Montreal Can (0.10%), Ingalls & Snyder LLC (0.10%) and JPMorgan Chase & Co. (0.05%).

How do I buy shares of Eupraxia Pharmaceuticals?

Shares of EPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Eupraxia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eupraxia Pharmaceuticals investors own include Aeterna Zentaris (AEZS), BlackBerry (BB), Bausch Health Cos (BHC), Bitfarms (BITF), Ballard Power Systems (BLDP), Cardiol Therapeutics (CRDL) and Fury Gold Mines (FURY).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 9/07/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EPRX
• Previous Symbol: NASDAQ:EPRX
• CIK: 1581178
• Web: www.eupraxiapharma.com
• Phone: 250-590-3968
• Fax: N/A
• Employees: 29
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Eupraxia Pharmaceuticals: $11.00
• High Price Target: $12.00
• Low Price Target: $9.00
• Potential Upside/Downside: +104.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.50 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -367.73%
• Return on Assets: -118.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.72
• Quick Ratio: 8.72

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 35,960,000
• Free Float: N/A
• Market Cap: $193.82 million
• Optionable: N/A
• Beta: 1.49